Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/31588
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18074/20272 (89%)
Visitors : 4307958      Online Users : 5772
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31588


    Title: PSMB5 plays a dual role in cancer development and immunosuppression
    Authors: Wang, Chih-Yang
    Li, Chung-Yen
    Hsu, Hui-Ping
    Cho, Chien-Yu
    Yen, Meng-Chi
    Weng, Tzu-Yang
    Chen, Wei-Ching
    Hung, Yu-Hsuan
    Lee, Kuo-Ting
    Hung, Jui-Hsiang
    Chen, Yi-Ling
    Lai, Ming-Derg
    Contributors: Natl Cheng Kung Univ, Dept Biochem & Mol Biol
    Natl Cheng Kung Univ, Inst Basic Med Sci
    Natl Cheng Kung Univ, Dept Surg, Coll Med
    Kaohsiung Med Univ Hosp,Kaohsiung Med Univ, Dept Emergency Med
    Chia Nan Univ Pharm & Sci, Dept Biotechnol
    Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management
    Keywords: Breast cancer
    proteasome
    PSMB5
    macrophage
    bioinformatics
    Date: 2017
    Issue Date: 2018-11-30 15:49:20 (UTC+8)
    Publisher: E-Century Publishing Corp
    Abstract: Tumor progression and metastasis are dependent on the intrinsic properties of tumor cells and the influence of microenvironment including the immune system. It would be important to identify target drug that can inhibit cancer cell and activate immune cells. Proteasome beta subunits (PSMB) family, one component of the ubiquitin-proteasome system, has been demonstrated to play an important role in tumor cells and immune cells. Therefore, we used a bioinformatics approach to examine the potential role of PSMB family. Analysis of breast TCGA and METABRIC database revealed that high expression of PSMB5 was observed in breast cancer tissue and that high expression of PSMB5 predicted worse survival. In addition, high expression of PSMB5 was observed in M2 macrophages. Based on our bioinformatics analysis, we hypothesized that PSMB5 contained immunosuppressive and oncogenic characteristics. To study the effects of PSMB5 on the cancer cell and macrophage in vitro, we silenced PSMB5 expression with shRNA in THP-1 monocytes and MDA-MB-231 cells respectively. Knockdown of PSMB5 promoted human THP-1 monocyte differentiation into M1 macrophage. On the other hand, knockdown PSMB5 gene expression inhibited MDA-MB-231 cell growth and migration by colony formation assay and boyden chamber. Collectively, our data demonstrated that delivery of PSMB5 shRNA suppressed cell growth and activated defensive M1 macrophages in vitro. Furthermore, lentiviral delivery of PSMB5 shRNA significantly decreased tumor growth in a subcutaneous mouse model. In conclusion, our bioinformatics study and functional experiments revealed that PSMB5 served as novel cancer therapeutic targets. These results also demonstrated a novel translational approach to improve cancer immunotherapy.
    Relation: American Journal of Cancer Research, v.7, n.11, pp.2103-2120
    Appears in Collections:[Dept. of Senior Service and Health Management] Periodical Articles
    [Dept. of Biotechnology (including master's program)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ajcr0007-2103.pdf3291KbAdobe PDF0View/Open
    index.html0KbHTML1320View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback